A Bioavailability and Food Effect Study of Venetoclax New High Drug Load Tablet Formulation in Healthy Female Subjects
Latest Information Update: 25 Jun 2024
At a glance
- Drugs Venetoclax (Primary)
- Indications Acute myeloid leukaemia; B-cell lymphoma; Blastic plasmacytoid dendritic cell neoplasm; Breast cancer; Cancer; Chronic lymphocytic leukaemia; Chronic myelomonocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Myelodysplastic syndromes; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Small cell lung cancer; T-cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AbbVie
- 20 Jun 2024 Planned End Date changed from 25 Feb 2024 to 28 Jul 2025.
- 20 Jun 2024 Planned primary completion date changed from 25 Feb 2024 to 28 Jul 2025.
- 20 Jun 2024 Planned initiation date changed from 2 Oct 2023 to 5 Oct 2023.